{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
angiotensin ii
to a specific field?
Status:
Investigational
Source:
NCT01300026: Phase 1 Interventional Completed Cancer
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
AMG-319 is an oral, small molecule inhibitor of PI3Kdelta which is now being tested in phase II for the treatment of head and neck squamous cell carcinoma and in phase I for lymphoid malignancy.
Status:
Investigational
Source:
NCT01374438: Phase 2 Interventional Completed Alzheimer's Disease
(2011)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Mitoglitazone (previously known as MSDC-0160 or CAY-10415) is a mTOT (mitochondrial target of thiazolidinediones) modulator that targets the mitochondrial pyruvate carrier (MPC), which is a key controller of cellular metabolism. MSDC-0160 is modulated MPC and act as insulin sensitizers without activating PPAR gamma. (Mitoglitazone exhibits very low binding affinity and activity at PPARγ). Mitoglitazone has been used in trials phase II studying the treatment of Type 2 Diabetes and Alzheimer's disease; the treatment for diabetes was discontinued. In addition, MSDC-0160 has demonstrated significant neuroprotective effects in the En1+/- mouse model of Parkinson’s disease via modulation of the mTOR-autophagy signaling cascade.
Status:
Investigational
Source:
NCT04337463: Phase 1/Phase 2 Interventional Unknown status Advanced Solid Tumor
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
CC-223 is an orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor CC-223 inhibits the activity of mTOR, which may result in the induction of tumor cell apoptosis and a decrease in tumor cell proliferation. CC-223 disrupted mitochondrial function, and induced mitochondrial permeability transition pore (mPTP) opening and reactive oxygen species (ROS) production. CC-223 is currently in phase II clinical trials for the treatment of Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours. The most common treatment-related adverse events were hyperglycemia, fatigue and rash.
Status:
Investigational
Source:
NCT01548703: Phase 1 Interventional Completed Healthy
(2012)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Fasidotril is a diester prodrug of the active metabolite fasidotrilat. Fasidotrilat inhibited both angiotensin I converting enzyme (ACE, EC 3.4.25.1) and neprilysin (NEP, EC 3.4.24.11, also named neutral endopeptidase, enkephalinase, or atriopeptidase) at nanomolar concentrations (Ki = 9.8 nM
against ACE and 5.1 nM against NEP)
Fasidotril was being developed for the treatment of myocardial infarction, congestive heart failure and myocardial infarction.
Status:
Investigational
Source:
NCT02909777: Phase 1 Interventional Active, not recruiting Lymphoma
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
CUDC-907 is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multiple myeloma, breast cancer and other malignancies.
Status:
Investigational
Source:
NCT02711553: Phase 2 Interventional Active, not recruiting Biliary Tract Cancer
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Merestinib (LY2801653) is a small molecule that has been shown in vitro to be a reversible type II ATP-competitive slowoff inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min−1 and a half-life (t1/2) of 525 min. Preclinical testing also has shown merestinib to inhibit several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, NTRK1/2/3, and DDR1/2 and the serine/threonine kinases MKNK1/2. Merestinib is being investigated in a phase II clinical trials in patients with biliary tract cancer, non-small cell lung cancer and solid tumours.
Status:
Investigational
Source:
NCT00517439: Phase 2 Interventional Completed Hepatitis C, Chronic
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
R1479 (4′-azidocytidine) is a specific inhibitor of hepatitis C virus (HCV) replication. 4′-azidocytidine triphosphate is an inhibitor of native HCV replicase and recombinant HCV polymerase (NS5B). Balapiravir (R1626) is the tri-isobutyrate ester prodrug of R1479 under clinical development to improve exposure of R1479 upon oral administration.
Status:
Investigational
Source:
NCT01256775: Phase 2 Interventional Completed Intermittent Claudication
(2003)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
NCX-4016, a nitric oxide non-steroidal anti-inflammatory drug (NO-NSAID) which can inhibit cyclooxygenase as well as release nitric oxide, is under development by NicOx as a potential treatment for thrombosis, inflammation and rheumatoid arthritis. NCX-4016 possesses a broad spectrum of antithrombotic and antiinflammatory activities. NCX-4016 has been shown to inhibit platelet activation in vitro more effectively than aspirin, to inhibit smooth muscle cell proliferation, to exert an endothelial cell protective activity and to suppress the function of several inflammatory cells potentially involved in atherothrombosis. In animal models, NCX-4016 protected from platelet thromboembolism, prevented restenosis in atherosclerosis-prone animals, protected the heart from ischemia/reperfusion injury, and induced neoangiogenesis in critically ischemic limbs. Moreover, it displayed little or no gastric toxicity and appeared to protect stomach from noxious stimuli, including aspirin. NCX-4016 has been evaluated in healthy volunteers and found to inhibit platelet cyclo-oxygenase-1 (COX-1) similarly to or slightly less than aspirin, to raise the circulating levels of NO-degradation products, and to have little or no gastric toxicity in short term studies. NCX-4016 was in Phase II clinical trials for the treatment of vascular disorders such as peripheral vascular disease and other cardiovascular diseases including thrombosis, complications of endothelium-related diseases such as diabetes and other. But this research was discontinued.
Status:
Investigational
Source:
NCT01234506: Phase 2 Interventional Completed Oxidative Stress
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Secoisolariciresinol diglucoside (SDG) isolated from flaxseed is a lipid-lowering and antioxidant agent. It suppresses the development of hypercholesterolemic atherosclerosis in rabbits. Secoisolariciresinol diglucoside has been shown to have antioxidant and cardioprotective properties. SDG interferes with the development of different types of
diseases like cardiovascular, diabetic, lupus nephritis, bone, kidney, menopause, reproduction, mental stress,
immunity, atherosclerosis, hemopoietic, liver necrosis and urinary disorders due to its various biological properties
including anti-inflammatory, antioxidant, antimutagenic, antimicrobial, antiobesity, antihypolipidemic and
neuroprotective effects. Moreover, SDG has a defending mediator against various cancers by modulating multiple
cell signaling pathways. The animal and human studies have shown the prevention
role of SDG against some cancers (breast, lung and
colon) as a result of its strong anti-proliferative, antioxidant,
anti-oestrogenic and/or anti-angiogenic activity. It
is proposed that the anticancer activity of SDG is associated
with the inhibition of enzymes involved in carcinogenesis. Human studies showed the SDG as potential
cardiovascular protector by mediating the mechanisms
of total cholesterol, LDL-cholesterol, HDL-cholesterol,
triacylglycerides and glucose metabolism. It was observed
that 20 hypercholesterolaemia and hypertriglyceridaemia
subjects receiving 600 mg SDG per day for
8 weeks led to significant reductions in total cholesterol,
LDL-cholesterol and glucose concentrations compared
with the placebo group. The animal and human studies revealed
that high fat diet containing 0 · 5 to 1 · 0 % SDG reduces
liver triglycerides content, serum triglycerides, total
cholesterol, and insulin and leptin concentrations that
resulted in significantly reduced visceral fat gain as compared
to group of mice receiving high fat diet without
SDG. SDG reduces C-reactive protein concentrations
which are associated with insulin resistance and diabetes
mellitus in type 2 diabetics. Daily consumption of
low-fat muffin enriched with SDG (500 mg/day) for
6 week can reduce CRP concentrations. SDG has
long acting hypotensive effect mediated through the guanylate
cyclase enzyme.
